Bisphosphonates appear to reduce a patient’s risk of colorectal cancer by 16%, with risedronate reducing it by up to 50%, a trial concludes.
If the findings are confirmed in other research, risedronate may turn out to be the drug of choice in people with osteoporosis and a high risk of colorectal cancer, the authors of the Canadian observational study said.
Using linked registries, they enrolled about 5,500 CRC patients and 55,000 matched controls.
In a multivariate analysis, exposure to bisphosphonates was associated with a 16% reduction
in the risk of CRC, although with wide confidence intervals (0.71-1.0).
When the researchers examined the effect of individual bisphosphonates, only risedronate maintained a significant association, halving the risk of CRC (CI = 0.3-0.85).
The researchers failed to...
This site is intended for Registered Medical Practitioners.
To make the most of Endocrinology Update, you need to be logged in.